Intestinal microbiome associated with development of grade 3/4 adverse in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (N/I) and probiotic support: Results from a phase Ib study.
Meza L, Dizman N, Bergerot P, Dorff T, Lyou Y, Frankel P, Llamas M, Hsu J, Zengin Z, Salgia N, Malhotra J, Chawla N, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Highlander S, Pal S. Intestinal microbiome associated with development of grade 3/4 adverse in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (N/I) and probiotic support: Results from a phase Ib study. Journal Of Clinical Oncology 2022, 40: 374-374. DOI: 10.1200/jco.2022.40.6_suppl.374.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaSetting of mRCCStool microbiome compositionPhase Ib studyWeeks of therapyFirst-line treatmentLung cancer patientsRenal cell carcinomaMicrobiome compositionDevelopment of treatmentsB. thetaiotamicronMedian followMRCC patientsAdverse eventsData cutoffOverall cohortIntervention armLine treatmentCell carcinomaCancer patientsTRAEsStool samplesStool specimensIntestinal microbiomeLarge cohortAssociation of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC).
Meza L, Choi Y, Govindarajan A, Dizman N, Zengin Z, Hsu J, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Castro D, Chan A, Zhang G, Byron S, Highlander S, Schork N, Pal S. Association of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 372-372. DOI: 10.1200/jco.2022.40.6_suppl.372.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsClear cell histologyFirst-line treatmentRoutine clinical careRenal cell carcinomaT-testPaucity of dataStudent's t-testParaffin-embedded samplesICI respondersICI therapyCheckpoint inhibitorsCell histologyClinical responseOverall cohortLine treatmentImmunotherapeutic agentsCell carcinomaPoor riskSpecific bacteriaLarge cohortClinical careICI activityPrimary site